Questions? Call 800-624-6242 About | Ordering | New Menu | Items in cart [0] SEARCH

PAPERBACK price:$21.00 add to cart Rights & Permissions Free PDF Access Sign in to download PDF book and chapters Free Resources Display this book on your site! Related Titles Evolution of Translational Omics: Lessons Learned and the Path Forward Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment Other Related Titles Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary (2010) National Cancer Policy Forum (NCPF) Board on Health Care Services (HCS) Citation Manager Export the bibliographic data for this book in your chosen format Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Citation Manager . "Acronyms." Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. Washington, DC: The National Academies Press, 2010. Please select a format: Page 71   E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Acronyms ACCE Analytic validity; Clinical validity; Clinical utility; and Ethical, legal, and social implications AHRQ Agency for Healthcare Research and Quality AML acute myelogenous leukemia ASCO American Society of Clinical Oncology CALGB Cancer and Leukemia Group B CAP College of American Pathologists CDC Centers for Disease Control and Prevention CDRH Center for Devices and Radiological Health CF cystic fibrosis CHOP cyclophosphamide, doxorubicin, vincristine, prednisone therapy CLIA Clinical Laboratory Improvement Amendments CMS Centers for Medicare & Medicaid Services CPT current procedural terminology EGAPP Evaluation of Genomic Applications in Practice and Prevention EGFR epidermal growth factor receptor EMEA European Medicines Agency ER estrogen receptor Page 71 Front Matter (R1-R12) Introduction (1-2) Personalized Cancer Medicine Technology (3-24) Regulation of Predictive Tests (25-48) Reimbursement (49-62) Summary (63-64) References (65-70) Acronyms (71-72) Glossary (73-76) Appendix A: Workshop Agenda (77-80) Appendix B: Workshop Speakers and Moderators (81-82)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 71
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary Acronyms ACCE Analytic validity; Clinical validity; Clinical utility; and Ethical, legal, and social implications AHRQ Agency for Healthcare Research and Quality AML acute myelogenous leukemia ASCO American Society of Clinical Oncology CALGB Cancer and Leukemia Group B CAP College of American Pathologists CDC Centers for Disease Control and Prevention CDRH Center for Devices and Radiological Health CF cystic fibrosis CHOP cyclophosphamide, doxorubicin, vincristine, prednisone therapy CLIA Clinical Laboratory Improvement Amendments CMS Centers for Medicare & Medicaid Services CPT current procedural terminology EGAPP Evaluation of Genomic Applications in Practice and Prevention EGFR epidermal growth factor receptor EMEA European Medicines Agency ER estrogen receptor

OCR for page 72
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary FDA Food and Drug Administration FISH fluorescent in situ hybridization FLT3 FMS-like tyrosine kinase 3 GAPPNet Genomic Applications in Practice and Prevention Network HER2 human epidermal growth factor receptor 2 HHS U.S. Department of Health and Human Services HRSA Health Resources and Services Administration IOM Institute of Medicine IVDMIA In Vitro Diagnostic Multivariate Index Assay KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog MEDCAC Medicare Evidence Development and Coverage Advisory Committee NCI National Cancer Institute NIH National Institutes of Health NLA national limitation amount OIVD Office of In Vitro Diagnostic Devices PCR polymerase chain reaction PET positron emission tomography PFS progression-free survival PMA premarket application PSA prostate-specific antigen SACGHS Secretary’s Advisory Committee on Genetics, Health, and Society SACGT Secretary’s Advisory Committee on Genetic Testing UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 USPSTF U.S. Preventive Services Task Force